HMGB1 and neoplasm: By the fact that up to 11% of NB patients had HMGB1 overexpression in tumors (Table 2) and this was associated with the increased risk of adverse events including tumor progression, relapse, or death (Figure 5), antitumor immunity mediated by HMGB1-induced Treg differentiation may be responsible for unfavorable outcomes.